A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions

Advanced Solid Tumors Harboring RAS Mutations or Amplifications

Interventions

DRUG

HRS-2329 Tablet

Oral HRS-2329 tablet.

Trial Locations (1)

Tianjin Medical University Cancer Institute and Hospital, Tianjin

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY